TMBR Timber Pharmaceuticals Inc

3.03
0.00 (0.0%)
Pre Market
Last Updated: 04:00:00
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Period:

Draw Mode:

Volume 0
Bid Price
Ask Price
News -
Day High

Low
1.20

52 Week Range

High
6.00

Day Low
Company Name Stock Ticker Symbol Market Type
Timber Pharmaceuticals Inc TMBR AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 3.03 04:00:00
Open Price Low Price High Price Close Price Prev Close
3.03
Trades Volume Avg Volume 52 Week Range
0 0 - 1.20 - 6.00
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 3.03 USD

Timber Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
9.35M 3.09M - 83k -19.38M -6.28 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Timber Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TMBR Message Board. Create One! See More Posts on TMBR Message Board See More Message Board Posts

Historical TMBR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.083.102.97693.0119,947-0.05-1.62%
1 Month3.063.132.97693.0538,335-0.03-0.98%
3 Months2.153.361.282.93397,1480.8840.93%
6 Months1.783.361.282.34417,4021.2570.22%
1 Year5.506.001.203.411,118,814-2.47-44.91%
3 Years47.34182.501.2042.213,189,083-44.31-93.6%
5 Years205.50208.501.2044.322,932,227-202.47-98.53%

Timber Pharmaceuticals Description

Timber Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. It is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and scleroderma. The company's development pipeline includes TMB-001 (Topical Isotretinoin), TMB-002 (Topical Rapamycin), and TMB-003 (Topical / Subcutaneous ET-A Receptor Antagonist).